ACB $2.920 (-5.5%)

ACNNF $0.042 (0%)

AERO $3.210 (0%)

ALEAF $0.066 (-12.25%)

AMMJ $0.054 (-9.87%)

APHA $15.380 (0%)

ARNA $99.990 (0%)

ATT:CNX $0.080 (0%)

AUSA:CNX $0.075 (0%)

AUSAF $0.063 (9.39%)

AVXL $8.720 (-7.53%)

BAMM:CNX $0.180 (-12.2%)

BBM:CNX $0.040 (0%)

BBRRF $0.036 (2.29%)

BE:CNX $0.005 (0%)

BIO:CNX $0.025 (0%)

BLIS:CNX $0.315 (0%)

BLO:CNX $0.580 (1.75%)

BLOZF $0.434 (-3.57%)

BUDZ $0.185 (-0.11%)

CADMF $0.140 (0%)

CALI:CNX $0.115 (-4.17%)

CANN $0.310 (5.05%)

CARA $8.370 (-6.38%)

CBWTF $0.125 (5%)

CGC $5.590 (-5.09%)

CGRW $0.024 (20.6%)

CHOO:CNX $0.005 (0%)

CHOOF $0.002 (-36.99%)

CNGGF $0.249 (0%)

CODI $22.240 (-3.93%)

CPMD $0.010 (-5.88%)

CRBP $0.330 (11.41%)

CRON $3.320 (-6.21%)

CROP:CNX $0.015 (0%)

CSI:CNX $0.185 (0%)

CURR $0.310 (0%)

CVSI $0.048 (-20.41%)

DIGP $0.019 (5.56%)

EEVVF $0.078 (0%)

EMHTF $0.033 (-15.24%)

EPWCF $0.080 (0%)

FFT:CNX $0.040 (0%)

FNNZF $0.080 (10.8%)

GNBT $0.002 (5.26%)

GRIN:CNX $0.070 (0%)

GRWG $5.090 (-12.24%)

GTBIF $11.670 (-4.27%)

GTII:CNX $15.000 (-3.29%)

GWPH $218.960 (0%)

HEXO $0.289 (-11.11%)

HHPHF $0.080 (0%)

HLSPY $0.363 (0%)

HMLSF $3.394 (-4.39%)

HMPPF $0.498 (0%)

HRVOF $0.027 (-0.06%)

HSTRF $0.135 (0%)

HUGE:CNX $1.150 (-5.74%)

IAN:CNX $0.090 (-14.29%)

IGC $0.450 (-7.9%)

IGXT $0.330 (4.6%)

IIPR $128.110 (-5.82%)

INQD $0.006 (-5%)

IONC:CNX $0.005 (0%)

IONKF $0.003 (-15%)

ISOL:CNX $0.035 (0%)

ITHUF $0.079 (-9.73%)

KBEV:CNX $0.045 (0%)

KHRNF $0.120 (-7.05%)

KSHB $0.695 (0%)

LHS:CNX $1.470 (0%)

LHSIF $1.145 (0%)

LXX:CNX $8.400 (0%)

MCIG $0.028 (0%)

MEDIF $0.060 (-16.08%)

MGWFF $0.075 (-15.92%)

MJ:CNX $0.100 (0%)

MJNA $0.016 (-2.45%)

MNTR $0.054 (0%)

MYM:CNX $0.140 (0%)

MYMMF $0.106 (0%)

NCNNF $0.058 (0%)

NDVAF $0.193 (5.34%)

NGW:CNX $0.410 (0%)

NRXCF $0.022 (0%)

NSPDF $0.012 (0%)

NVTQF $0.513 (5.6%)

NWKRF $0.424 (0%)

NXGWF $0.316 (0%)

NXTTF $0.047 (-0.84%)

OH:CNX $5.330 (0%)

ORHOF $4.050 (0%)

PHCG $0.025 (47.06%)

PHVAF $0.038 (0%)

PILL:CNX $0.240 (-11.11%)

PKG:CNX $0.025 (0%)

PLPRF $0.357 (0%)

PLUS:CNX $0.440 (0%)

PMCB $2.250 (-1.75%)

PNPL $0.011 (1.9%)

PTNYF $0.020 (-6.54%)

QCA:CNX $0.090 (-5.26%)

RDDTF $0.027 (4.98%)

RLLVF $0.001 (0%)

RMHB $0.015 (0%)

RQB:CNX $0.005 (0%)

RQHTF $0.457 (-6.35%)

SLNG:CNX $0.155 (3.33%)

SMG $89.130 (-9.71%)

SNN:CNX $0.155 (0%)

SOL:CNX $0.800 (-3.61%)

SOLCF $0.625 (-2.86%)

SPLIF $0.028 (1.45%)

SPRWF $0.268 (0%)

STEM:CNX $0.045 (-10%)

STMH $0.035 (-14.14%)

SUN:CNX $0.150 (0%)

TBPMF $0.051 (17.91%)

TCAN:CNX $0.120 (0%)

TCNAF $0.110 (0%)

TER:CNX $4.670 (-0.43%)

TGEN $1.350 (0%)

TGIF:CNX $0.030 (0%)

TGIFF $0.024 (2.16%)

THC:CNX $0.060 (50%)

THCBF $0.037 (-1.6%)

TLRY $4.790 (-6.81%)

TRLFF $0.060 (-9.47%)

TRSSF $3.635 (-0.95%)

VIDA:CNX $0.055 (0%)

VIN:CNX $0.020 (0%)

VPRB $0.049 (0%)

VRTHF $0.040 (0%)

VVCIF $0.040 (2.56%)

WAYL:CNX $0.740 (0%)

XXII $1.770 (-7.33%)

ZDPY $0.775 (9.15%)

ZYNE $0.920 (-7.37%)

Technical420 Site Search

Returned 148 result(s).

MediPharm Labs Enters United States Pharmaceutical Market with Submission of FDA DMF

MediPharm Labs Corp. (TSX: LABS) (OTCQX: MEDIF) (FSE: MLZ) a pharmaceutical company specialized in precision-based cannabinoids, is pleased to announce it has completed a US FDA DMF for pure natural CBD API. The DMF will enable MediPharm to supply approved API to pharmaceutical companies currently conducting late-stage research. The cannabis-based drug…

MediPharm Labs Completes Payment of All Convertible Debt

MediPharm Labs Corp. (TSXV: LABS) (OTCQX: MEDIF) (FSE: MLZ) (“MediPharm Labs” or the “Company”) a pharmaceutical company specialized in precision-based cannabinoids, is pleased to announce that it has completed all payments required under its 2020 $41 million unsecured convertible debt. “MediPharm continues on its plan and path to profitability, and…

MediPharm Labs Provides Operational Update and Confirms Profitability Improvement Initiatives are Underway

MediPharm Labs Corp. (TSXV: LABS) (OTCQX: MEDIF) (FSE: MLZ) a pharmaceutical company specialized in precision-based cannabinoids, is pleased to provide an update on the significant strategic profitability improvement initiatives underway at the Company. “Although the cannabis industry has seen a pull back in the capital markets, I remain extremely positive…

MediPharm Labs Completes Medical Cannabis Export to Barbados

MediPharm Labs Corp. (TSX: LABS) (OTCQX: MEDIF) (FSE: MLZ) a pharmaceutical company specialized in precision-based cannabinoids, is pleased to announce it has completed a medical cannabis export to Barbados in conjunction with strategic partner Avicanna (TSX: AVCN). “Our GMP platform make us the go-to partner for companies looking to access…

MediPharm Labs Expands CBN Portfolio with Two New Products

MediPharm Labs Corp. (TSX: LABS) (OTCQX: MEDIF) (FSE: MLZ) a pharmaceutical company specialized in precision-based cannabinoids, is pleased to announce the expansion of its unique cannabinol (“CBN”) product line. “Once again MediPharm Labs continues to innovate and commercialize unique cannabinoids. Our exciting new CBN:CBD is a unique formulation that allows…

MediPharm Reports Third Quarter 2021 Results; Announces New CEO to Start Today

MediPharm Labs Corp. (TSX: LABS) (OTCQX: MEDIF) (FSE: MLZ) a pharmaceutical company specialized in precision-based cannabinoids today announced its financial results for the three and nine months ended September 30, 2021, a period of transition in establishing itself as an international pharmaceutical company specializing in cannabis. Q3 2021 Key Highlights…

MediPharm Labs Receives Export Authorization to Ship Medical Cannabis to Brazil

MediPharm Labs Corp. (TSX: LABS) (OTCQX: MEDIF) (FSE: MLZ) (“MediPharm Labs” or the “Company”) a pharmaceutical company that specializes in cannabis, is pleased to announce that it has received approval to ship medical cannabis oil to Brazil. This approval, issued by both ANVISA and Health Canada, allows initial shipments to…

MediPharm Reports Second Quarter 2021 Results and Advances Pharmaceutical Strategy; Announces new Board Chair

MediPharm Labs Corp. (TSX: LABS) (OTCQX: MEDIF) (FSE: MLZ) (“MediPharm” or the “Company”) a pharmaceutical company specialized in research-driven development and manufacturing of cannabis API and finished dose products today announced its financial results for the three and six months ended June 30, 2021, a period of ongoing progress in…

MediPharm Labs Sets Date to Report Second Quarter 2021 Financial Results

MediPharm Labs Corp. (TSX: LABS) (OTCQX: MEDIF) (FSE: MLZ) a pharmaceutical company specialized in research-driven development and manufacturing of cannabis API and finished products, is pleased to announce it will release second quarter financial results for the three and six month period ended June 30, 2021 before markets open on…

Medipharm Labs Is One Of The Most Misunderstood Companies In The Canadian Cannabis Sector

We consider MediPharm Labs Corp. (TSX: LABS) (OTCQX: MEDIF) (FSE: MLZ) to be one of the most misunderstood growth stories in the cannabis industry and are favorable on how the business has advanced since 2020. From entering new international markets to advancing initiatives that are focused on the biotech side…

Older Posts »

Search Again